Research Blends
GLOW
GLOW groups GHK-Cu, BPC-157 and a TB-500-listed component, bringing together separate lines of matrix-remodeling and tissue-signaling research.
$144USD / vial · 70 mg
Research only Research blend
Tesamorelin + Ipamorelin
Catalog size
$86
USD per vial · 10 mgCatalog price
Research onlyTesamorelin + Ipamorelin combines two distinct endocrine research materials, with clinical evidence for individual compounds that does not validate the combined formulation.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
No reservation or purchase is made by adding a material.
View documentation status ← Back to collection- Listed components
- Tesamorelin 5 mg + Ipamorelin 5 mg
- Format
- Awaiting confirmation
- Batch reports
- Check this size in the COA library
- Availability
- Confirmed during review
Catalog quantities are not assay results.
In the literature
The components. The research context.
GHRH analogue and growth-hormone secretagogue research blend
Understanding the formulation
Tesamorelin is a stabilized analogue of growth hormone-releasing hormone. Ipamorelin is a synthetic pentapeptide secretagogue associated with the ghrelin receptor. Their shared relationship to endogenous growth-hormone release does not make them interchangeable. The three catalog sizes use different component quantities, including both equal and unequal ratios.
- Research class
- GHRH analogue and growth-hormone secretagogue research blend
- Catalog search names
- Tesa Ipa · Tesamorelin / Ipamorelin
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Why these components are studied
Tesamorelin engages the pituitary GHRH signaling system; ipamorelin acts through a different secretagogue pathway. Endocrine feedback, available pituitary function and the surrounding physiological state influence responses. Combining two pathways creates an experimental question, but does not establish a particular pulse pattern, increased selectivity or a superior clinical effect.
Component and related research
These links provide research context; they do not confirm the exact materials in this formulation.
Documented lines of inquiry
Research areas
- 01
Disease-specific body-composition research
A controlled tesamorelin trial evaluated people with HIV-associated abdominal fat accumulation. Its population and defined pharmaceutical preparation do not establish general weight-loss effects or efficacy of this blend. [1]
- 02
Visceral and hepatic fat endpoints
Another tesamorelin trial measured visceral and liver fat in a specified clinical population. Imaging changes should be distinguished from long-term clinical events and from effects of a two-peptide mixture. [2]
- 03
Exposure and hormone response
A human ipamorelin study modeled pharmacokinetics and growth-hormone secretion. It provides physiological information about ipamorelin alone, not a test of tesamorelin coformulation. [3]
Study topics describe the cited models, not established benefits of this catalog material.
Reading the evidenceWhat the studies
Component evidence · finished blend untested in cited studies
What the studies
can tell us.
Component evidence · finished blend untested in cited studiesTesamorelin has controlled human evidence for particular endpoints in defined populations. Ipamorelin has human endocrine studies and a separate clinical development history. Their individual evidence bases do not demonstrate safety, efficacy or synergy of the combined catalog product.
What remains uncertain
Results for clinical tesamorelin formulations should not be generalized to healthy people or transferred to WYZ materials. The catalog ratios were not compared in the cited trials. Component identity, stability and finished-mixture testing remain separate questions requiring product-specific documentation.
Read the source
Selected literature
These papers concern individual components or related molecules. They do not validate this finished blend.
- 01PubMed
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension (opens a new tab)
Randomized trial in HIV-associated abdominal adiposity; not a general weight-loss population.
- 02PubMed
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial (opens a new tab)
Placebo-controlled trial measuring visceral and hepatic fat; long-term clinical consequences remained uncertain.
- 03PubMed
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens a new tab)
Healthy-volunteer endocrine kinetics; not a long-term efficacy study.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Before you begin
The details behind
the material.
Specifications and storage
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
Research use only
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAContinue exploring.
All materialsOther research blends in the collection.
View details
Research Blends
KLOW
KLOW lists GHK-Cu, BPC-157, TB-500 and KPV, connecting component studies of skin-matrix remodeling, cell migration and intestinal inflammatory signaling.
$129USD / vial · 80 mg
Research only
Research Blends
Wolverine
Wolverine pairs BPC-157 with a TB-500-listed component, connecting preclinical tendon and gastrointestinal research with thymosin-related identity questions. The exact TB-500 sequence still requires confirmation.
$65USD / vial · 10 mg
Research only